March 8 (Reuters) - Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.
The company said its plans for the drug may include voluntarily withdrawing it from the market. (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
The $50 million purchase could turn into Nvidia's biggest investment.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The tobacco giant will soon be allowed to sell a proven product in a proven market.
Earnings presentations from four of the biggest tech companies in the world showed two very different visions of AI: the moonshot and the incremental gains.